Implantable contraceptives for women

Olav Meirik; Ian S. Fraser; Catherine d'Arcangues; Biran Affandi; Vivian Branche; Davy Chikamata; Horacio Croxatto; Kate Curtis; Soledad Diaz; Laneta Dorflinger; Lindsay Edouard; Mawaheb Tawhid El-Mouelhy; Anibal Faundes; Henry Gabelnick; Anna Glasier; Han Li-Hui; Martha Hickey; Carlos Huezo; Alex Jordan; Rose Kithinji; Tekle Ab Mekbib; Suellen Miller; Nuriye Ortayli; Herbert Peterson; Ida Proemono; Kathleen Rodgers; Eka Rusdianto; Prasad Shastri; Irving Sivin

doi:10.1093/humupd/dmg004

Implantable contraceptives for women

Olav Meirik, Ian S. Fraser, Catherine d'Arcangues, Biran Affandi, Vivian Branche, Davy Chikamata, Horacio Croxatto, Kate Curtis, Soledad Diaz, Laneta Dorflinger, Lindsay Edouard, Mawaheb Tawhid El-Mouelhy, Anibal Faundes, Henry Gabelnick, Anna Glasier, Han Li-Hui, Martha Hickey, Carlos Huezo, Alex Jordan, Rose KithinjiTekle Ab Mekbib, Suellen Miller, Nuriye Ortayli, Herbert Peterson, Ida Proemono, Kathleen Rodgers, Eka Rusdianto, Prasad Shastri, Irving Sivin

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

Progestogen-only implantable contraceptives are used by increasing numbers of women worldwide. This review outlines the evidence accumulated on these methods to date. Reviews of toxicological evaluations, clinical trials, endocrinological, epidemiological and social science studies, as well as operations research and economic evaluation were undertaken in preparation for an Expert Consultation convened by the World Health Organization in 2001. At the meeting, these reviews were further evaluated and the research results summarized in this consensus paper. A large body of evidence demonstrates the high contraceptive effectiveness and safety of the 5-year levonorgestrel-releasing implants Norplant and Jadelle. Information on the 3-year etonogestrel-releasing implant Implanon is more limited, but suggests that this implant has a high contraceptive effectiveness and a satisfactory safety profile. Information available on levonorgestrel-releasing implants manufactured and approved in China suggests that their clinical performance is satisfactory, but was insufficient to allow their full safety assessment. For all implants, there is insufficient information on their use by women with medical conditions. Provision of contraceptive implants requires good quality family planning services and specific provider training.

Original language	English (US)
Pages (from-to)	49-59
Number of pages	11
Journal	Human Reproduction Update
Volume	9
Issue number	1
DOIs	https://doi.org/10.1093/humupd/dmg004
State	Published - Jan 2003
Externally published	Yes

Keywords

Contraception
Implant
Progestogen-only contraceptive
WHO consensus paper

ASJC Scopus subject areas

Reproductive Medicine
Obstetrics and Gynecology

Access to Document

10.1093/humupd/dmg004

Cite this

Meirik, O., Fraser, I. S., d'Arcangues, C., Affandi, B., Branche, V., Chikamata, D., Croxatto, H., Curtis, K., Diaz, S., Dorflinger, L., Edouard, L., El-Mouelhy, M. T., Faundes, A., Gabelnick, H., Glasier, A., Li-Hui, H., Hickey, M., Huezo, C., Jordan, A., ... Sivin, I. (2003). Implantable contraceptives for women. Human Reproduction Update, 9(1), 49-59. https://doi.org/10.1093/humupd/dmg004

Meirik, O, Fraser, IS, d'Arcangues, C, Affandi, B, Branche, V, Chikamata, D, Croxatto, H, Curtis, K, Diaz, S, Dorflinger, L, Edouard, L, El-Mouelhy, MT, Faundes, A, Gabelnick, H, Glasier, A, Li-Hui, H, Hickey, M, Huezo, C, Jordan, A, Kithinji, R, Mekbib, TA, Miller, S, Ortayli, N, Peterson, H, Proemono, I, Rodgers, K, Rusdianto, E, Shastri, P & Sivin, I 2003, 'Implantable contraceptives for women', Human Reproduction Update, vol. 9, no. 1, pp. 49-59. https://doi.org/10.1093/humupd/dmg004

@article{10660d9ec2674cb782a0843a6d4d0599,

title = "Implantable contraceptives for women",

abstract = "Progestogen-only implantable contraceptives are used by increasing numbers of women worldwide. This review outlines the evidence accumulated on these methods to date. Reviews of toxicological evaluations, clinical trials, endocrinological, epidemiological and social science studies, as well as operations research and economic evaluation were undertaken in preparation for an Expert Consultation convened by the World Health Organization in 2001. At the meeting, these reviews were further evaluated and the research results summarized in this consensus paper. A large body of evidence demonstrates the high contraceptive effectiveness and safety of the 5-year levonorgestrel-releasing implants Norplant and Jadelle. Information on the 3-year etonogestrel-releasing implant Implanon is more limited, but suggests that this implant has a high contraceptive effectiveness and a satisfactory safety profile. Information available on levonorgestrel-releasing implants manufactured and approved in China suggests that their clinical performance is satisfactory, but was insufficient to allow their full safety assessment. For all implants, there is insufficient information on their use by women with medical conditions. Provision of contraceptive implants requires good quality family planning services and specific provider training.",

keywords = "Contraception, Implant, Progestogen-only contraceptive, WHO consensus paper",

author = "Olav Meirik and Fraser, {Ian S.} and Catherine d'Arcangues and Biran Affandi and Vivian Branche and Davy Chikamata and Horacio Croxatto and Kate Curtis and Soledad Diaz and Laneta Dorflinger and Lindsay Edouard and El-Mouelhy, {Mawaheb Tawhid} and Anibal Faundes and Henry Gabelnick and Anna Glasier and Han Li-Hui and Martha Hickey and Carlos Huezo and Alex Jordan and Rose Kithinji and Mekbib, {Tekle Ab} and Suellen Miller and Nuriye Ortayli and Herbert Peterson and Ida Proemono and Kathleen Rodgers and Eka Rusdianto and Prasad Shastri and Irving Sivin",

year = "2003",

month = jan,

doi = "10.1093/humupd/dmg004",

language = "English (US)",

volume = "9",

pages = "49--59",

journal = "Human Reproduction Update",

issn = "1355-4786",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Implantable contraceptives for women

AU - Meirik, Olav

AU - Fraser, Ian S.

AU - d'Arcangues, Catherine

AU - Affandi, Biran

AU - Branche, Vivian

AU - Chikamata, Davy

AU - Croxatto, Horacio

AU - Curtis, Kate

AU - Diaz, Soledad

AU - Dorflinger, Laneta

AU - Edouard, Lindsay

AU - El-Mouelhy, Mawaheb Tawhid

AU - Faundes, Anibal

AU - Gabelnick, Henry

AU - Glasier, Anna

AU - Li-Hui, Han

AU - Hickey, Martha

AU - Huezo, Carlos

AU - Jordan, Alex

AU - Kithinji, Rose

AU - Mekbib, Tekle Ab

AU - Miller, Suellen

AU - Ortayli, Nuriye

AU - Peterson, Herbert

AU - Proemono, Ida

AU - Rodgers, Kathleen

AU - Rusdianto, Eka

AU - Shastri, Prasad

AU - Sivin, Irving

PY - 2003/1

Y1 - 2003/1

N2 - Progestogen-only implantable contraceptives are used by increasing numbers of women worldwide. This review outlines the evidence accumulated on these methods to date. Reviews of toxicological evaluations, clinical trials, endocrinological, epidemiological and social science studies, as well as operations research and economic evaluation were undertaken in preparation for an Expert Consultation convened by the World Health Organization in 2001. At the meeting, these reviews were further evaluated and the research results summarized in this consensus paper. A large body of evidence demonstrates the high contraceptive effectiveness and safety of the 5-year levonorgestrel-releasing implants Norplant and Jadelle. Information on the 3-year etonogestrel-releasing implant Implanon is more limited, but suggests that this implant has a high contraceptive effectiveness and a satisfactory safety profile. Information available on levonorgestrel-releasing implants manufactured and approved in China suggests that their clinical performance is satisfactory, but was insufficient to allow their full safety assessment. For all implants, there is insufficient information on their use by women with medical conditions. Provision of contraceptive implants requires good quality family planning services and specific provider training.

AB - Progestogen-only implantable contraceptives are used by increasing numbers of women worldwide. This review outlines the evidence accumulated on these methods to date. Reviews of toxicological evaluations, clinical trials, endocrinological, epidemiological and social science studies, as well as operations research and economic evaluation were undertaken in preparation for an Expert Consultation convened by the World Health Organization in 2001. At the meeting, these reviews were further evaluated and the research results summarized in this consensus paper. A large body of evidence demonstrates the high contraceptive effectiveness and safety of the 5-year levonorgestrel-releasing implants Norplant and Jadelle. Information on the 3-year etonogestrel-releasing implant Implanon is more limited, but suggests that this implant has a high contraceptive effectiveness and a satisfactory safety profile. Information available on levonorgestrel-releasing implants manufactured and approved in China suggests that their clinical performance is satisfactory, but was insufficient to allow their full safety assessment. For all implants, there is insufficient information on their use by women with medical conditions. Provision of contraceptive implants requires good quality family planning services and specific provider training.

KW - Contraception

KW - Implant

KW - Progestogen-only contraceptive

KW - WHO consensus paper

UR - http://www.scopus.com/inward/record.url?scp=0037219264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037219264&partnerID=8YFLogxK

U2 - 10.1093/humupd/dmg004

DO - 10.1093/humupd/dmg004

M3 - Review article

C2 - 12638781

AN - SCOPUS:0037219264

SN - 1355-4786

VL - 9

SP - 49

EP - 59

JO - Human Reproduction Update

JF - Human Reproduction Update

IS - 1

ER -

Implantable contraceptives for women

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this